bioMérieux: Good Q3 performance. Declining China leads to a shy upward revision in guidance

BUY, Fair Value EUR108 vs. EUR107 (+7%)
News published on October Thursday 22, 2015
Share on

BioMérieux Q3 sales topped consensus by 5% standing at EUR478.3m, up 16.1% year on year (8.8%cc), driven by strong performances in both EMEA with southern Europe recovering and the Americas with BioFire’s momentum. FY2015 organic sales growth guidance is now expected at around 6.5% vs. in the 4.5%-6.5% range previously. EBIT guidance in maintained at EUR240-265m to reflect continuous investments to support the launch of new products.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities